Drug maker Amgen Inc. says regulators have added new warnings about risks of death and tumor growth to its blockbuster anemia drugs.
The new warnings approved by the Food and Drug Administration
warn that the company's drugs increased death and accelerated tumor
growth in patients with several types of cancer, including breast
and cervical. Prior labeling warned of similar risks in other types
The warnings also apply to Thousand Oaks, Calif.-based Amgen's
Aranesp and Epogen, as well as Procit, made by New Brunswick,
N.J-based Johnson & Johnson.